[CAS NO. 1314883-11-8] MMV390048

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1314883-11-8]

Catalog

HY-106005

Brand

MCE

CAS

1314883-11-8

DESCRIPTION [1314883-11-8]

Overview

MDL	-
Molecular Weight	393.38
Molecular Formula	C18H14F3N3O2S
SMILES	NC1=NC=C(C2=CC=C(S(=O)(C)=O)C=C2)C=C1C3=CC=C(C(F)(F)F)N=C3

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Antimicrob Agents Chemother. 2022 Aug 4;e0057422.

Summary

MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (K _d ^app =0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent ^[1] .

IC50 & Target

Plasmodium

In Vitro

MMV390048 against intraerythrocytic life cycle stages of P. falciparum (NF54 drug-sensitive strain) showed a steep inhibition curve with IC50 and IC90 values of 28 and 40 nM, respectively.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02230579	Medicines for Malaria Venture\|University of Cape Town	Malaria	May 2014	Phase 1
NCT03195387	Medicines for Malaria Venture\|Datamap\|PrimeVigilance Zagreb\|ICON Clinical Research\|Sanaria Inc.\|PTx Solutions Ltd., UK\|University of Cape Town	Malaria,Falciparum	January 2018	Phase 1
NCT02783833	Medicines for Malaria Venture\|Clinical Network Services (CNS) Pty Ltd\|Q-Pharm Pty Limited\|QIMR Berghofer Medical Research Institute	Malaria	May 2016	Phase 1\|Phase 2
NCT02281344	Medicines for Malaria Venture\|Q-Pharm Pty Limited	Malaria, Falciparum	October 2014	Phase 1
NCT02880241	Medicines for Malaria Venture\|University of Gondar\|Jimma University	Malaria	October 20, 2017	Phase 2
NCT02554799	Medicines for Malaria Venture\|Richmond Pharmacology Limited	Malaria	September 17, 2015	Phase 1
NCT02783820	Medicines for Malaria Venture\|Clinical Network Services (CNS) Pty Ltd\|Q-Pharm Pty Limited\|QIMR Berghofer Medical Research Institute	Malaria	May 2016	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 254.21 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5421 mL	12.7104 mL	25.4207 mL
5 mM	0.5084 mL	2.5421 mL	5.0841 mL
10 mM	0.2542 mL	1.2710 mL	2.5421 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.36 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Paquet T, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017 Apr 26;9(387). pii: eaad9735.